Disparate Response to Methotrexate in Stem Versus Non-Stem Cells
- 341 Downloads
Methotrexate (MTX) is a commonly used chemotherapeutic agent that kills cancer cells by binding dihydrofolate reductase (DHFR) as a competitive inhibitor. Due to its non-selectivity, MTX also impairs normal (non-cancerous) cell function and causes long-term damage to healthy tissue. These consequences have been investigated extensively in bone-derived cells due to their sensitivity to the drug. While DHFR likely plays a role in normal cell response to MTX, research in this area is limited. Moreover, how MTX sensitivity differs among cell types responsible for maintaining connective tissues is unknown. The goal of this study was to investigate the role of DHFR and subsequent nucleotide synthesis in normal cell response to MTX. We also sought to compare adverse effects of MTX among normal cell types to identify sensitive populations and resistant cell sources for regenerative procedures targeting patients undergoing chemotherapy. DHFR overexpression or exogenous amino acid + nucleoside delivery rescued normal cells from adverse MTX effects. Conversely, DHFR knockdown impaired MTX-treated adipose-derived stem cell (ASC) osteogenesis. Proliferation of ASCs and bone marrow stem cells was more resistant to MTX than that of terminally differentiated osteoblasts. However, stem cells became susceptible to the drug after beginning differentiation. These results suggest that the ability of stem cells to survive and to maintain their surrounding tissues likely depends on whether they are in a “stem” state when exposed to MTX. Therapeutic strategies that delay the differentiation of stem cells until clearance of the drug may produce more favorable outcomes in the long-term health of treated tissues.
KeywordsCancer Chemotherapy Mesenchymal stem cell Methotrexate Regenerative medicine
The authors would like to thank Jason Machan for advice on statistical analyses, Paul Liu and Mikki Ciombor for providing lipoaspirate samples, and Mark Dooner and the COBRE Flow Cytometry Core at Rhode Island Hospital for their assistance with FACS experiments. This work was supported by awards from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR063642; EMD), National Science Foundation (CAREER Award, CBET1253189; EMD), and a Staley Small Grant from Wellesley College (LEOD). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or National Science Foundation.
OSB, LEOD, and EMD designed the study and wrote the manuscript. OSB conducted all cell culture, Western blots, PCR, and assays for proliferation and differentiation. LEOD conducted all plasmid synthesis work. VCF assisted with histological staining.
Compliance with Ethical Standards
Conflict of Interest
The authors declare no potential conflict of interest.
- 7.Baum, B. J., Bodner, L., Fox, P. C., Izutsu, K. T., Pizzo, P. A., & Wright, W. E. (1985). Therapy-induced dysfunction of salivary glands: implications for oral health. Special Care in Dentistry: Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry, 5, 274–277.CrossRefGoogle Scholar
- 12.Early Breast Cancer Trialists' Collaborative G., Peto R., Davies C., et al. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379, 432–444.Google Scholar
- 31.Rosenblatt, D. S., Whitehead, V. M., Matiaszuk, N. V., Pottier, A., Vuchich, M. J., & Beaulieu, D. (1982). Differential effects of folinic acid and glycine, adenosine, and thymidine as rescue agents in methotrexate-treated human cells in relation to the accumulation of methotrexate polyglutamates. Molecular Pharmacology, 21, 718–722.PubMedGoogle Scholar
- 37.Reichert, J. C., Quent, V. M. C., Burke, L. J., Stansfield, S. H., Clements, J. A., & Hutmacher, D. W. (2010). Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials, 31, 7928–7936.CrossRefPubMedGoogle Scholar
- 49.Wolfrom, C., Hepp, R., Hartmann, R., Breithaupt, H., & Henze, G. (1990). Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. European Journal of Clinical Pharmacology, 39, 377–383.CrossRefPubMedGoogle Scholar
- 51.Colak, S., & Medema, J. P. (2014). Human colonic fibroblasts regulate stemness and chemotherapy resistance of colon cancer stem cells. Cell Cycle, 0.Google Scholar